Yes. Wegovy is semaglutide, and it is a GLP-1 receptor agonist: it acts on the receptor for GLP-1, a hormone the gut releases after eating.

No. Wegovy is a GLP-1 receptor agonist, not insulin: it acts on the body's own insulin release rather than replacing insulin. That is why these drugs' labels warn of low blood sugar mainly when they are taken with insulin or a sulfonylurea.

Does Wegovy come in a pill?

Not as Wegovy, which is an injection. The same molecule, semaglutide, is sold as a pill under Wegovy pill and Rybelsus.

What is Wegovy?

What is Wegovy, and how does it work?

Wegovy (semaglutide injection) is an injection made by Novo Nordisk, whose active ingredient is semaglutide. FDA approved for cardiovascular risk reduction, chronic weight management from age 12, and noncirrhotic MASH with moderate to advanced liver fibrosis at stages F2 to F3 — the last under accelerated approval, which the label says may be contingent on a confirmatory trial. It imitates a gut hormone the body already makes, binding the same receptor in the brain regions that regulate appetite. In its pivotal trial it produced 14.9% mean weight loss. It costs $349 a month once titrated, read from its own published page on 2026-09-22 — the maintenance rate rather than the starting dose, because the starting dose is not the dose anyone stays on.

How does Wegovy work? The label's words

Semaglutide is a GLP-1 analog with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological regulator of appetite and caloric intake, and the GLP-1 receptor is present in several areas of the brain involved in appetite regulation.

Quoted from the mechanism of action section of FDA prescribing information for WEGOVY, read 2026-08-29. Not paraphrased: how a drug works is the last thing a price site should put in its own words.

What is Wegovy approved for?

Cardiovascular risk reduction
To reduce the risk of major adverse cardiovascular events — cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke — in adults with established cardiovascular disease and either obesity or overweight.
Chronic weight management
To reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight in the presence of at least one weight-related comorbid condition.
MASH with moderate to advanced fibrosis
For the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH, with moderate to advanced liver fibrosis (stages F2 to F3) in adults. Approved under accelerated approval: continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial.

Approvals are quoted from the label, because the wording is what a prior authorization is judged against. Which approval a plan cannot exclude — a weight-loss exclusion is written against the use, not the molecule.

How much weight did Wegovy lose in its trial?

14.9% of body weight. STEP 1, Study 2 on the label (NCT03548935), 68 weeks: 14.9% mean weight loss at 2.4 mg against 2.4% on placebo, intention-to-treat.

One trial, one protocol, one population. Comparing it with another drug's figure compares two separate experiments rather than two drugs — the comparison, and what a point of body weight costs.

It carries a boxed warning — the strongest the FDA issues

In rodents this molecule caused thyroid C-cell tumors at human-relevant doses. Whether it does so in people is unknown, and the label carries that as a boxed warning. It is contraindicated outright with a personal or family history of medullary thyroid carcinoma or MEN 2.

Everything the label lists, including who cannot take it →

How much does Wegovy cost?

$349 a month once titrated, read from its own published page on 2026-09-22. The starting dose is usually cheaper and nobody stays on it, which is why the maintenance figure is the one this site records.

Wegovy price and terms →The cheapest way to get it →

No clinician has reviewed this page. Label and trial statements are quoted from the FDA label or the trial cited beside them. General guidance is marked as such, and every price carries the date it was verified. That is sourcing, not medical review. What we do and do not check · Who checked the price

Wegovy, answered

Is Wegovy a GLP-1?: Yes. Wegovy is semaglutide, and it is a GLP-1 receptor agonist: it acts on the receptor for GLP-1, a hormone the gut releases after eating.
Is Wegovy insulin?: No. Wegovy is a GLP-1 receptor agonist, not insulin: it acts on the body's own insulin release rather than replacing insulin. That is why these drugs' labels warn of low blood sugar mainly when they are taken with insulin or a sulfonylurea.
Does Wegovy come in a pill?: Not as Wegovy, which is an injection. The same molecule, semaglutide, is sold as a pill under Wegovy pill and Rybelsus.

Everything on Wegovy

Last updated 2026-08-29 — the FDA label this page quotes. Read and dated by Alex Seot.